Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir.
Assessment of 1177 human immunodeficiency virus (HIV) resistance genotypes at an HIV/AIDS clinic showed a decrease in the incidence of the K65R mutation, from 15.2% of isolates during the period 2002-2004 to 2.7% of isolates during the period 2005-2006 (P < .001), despite elevated and stable rates of tenofovir use. A reduction in the rate of coadministration of didanosine (from 41.6% of patients in 2004 to 0.8% of patients in 2006; P < .001) largely explained this observation.
de Mendoza
Carmen
C
Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain. cmendoza@teleline.es
Jiménez-Nacher
Inmaculada
I
Garrido
Carolina
C
Barreiro
Pablo
P
Poveda
Eva
E
Corral
Angélica
A
Zahonero
Natalia
N
González-Lahoz
Juan
J
Soriano
Vincent
V
D000225:Adenine / Q000031:analogs & derivatives / Q000494:pharmacology; D019380:Anti-HIV Agents / Q000494:pharmacology*; D016049:Didanosine / Q000494:pharmacology; D024921:Drug Resistance, Multiple, Viral / Q000235:genetics*; D015658:HIV Infections / Q000378:metabolism*; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors / Q000235:genetics*; D015497:HIV-1 / Q000187:drug effects / Q000201:enzymology / Q000235:genetics; D006801:Humans; D009154:Mutation; D063065:Organophosphonates / Q000494:pharmacology; D012189:Retrospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology*; D000068698:Tenofovir
D019380:Anti-HIV Agents; D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D000068698:Tenofovir; D054303:HIV Reverse Transcriptase; D000225:Adenine; D016049:Didanosine